Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study

Studies on autoantibody production in patients treated with tumor necrosis factor-α (TNF-α) inhibitors reported contradictory results. We investigated in a prospective study the efficacy of a treatment with human monoclonal anti-TNF-α antibody (adalimumab) in patients with rheumatoid arthritis (RA)...

Descripción completa

Detalles Bibliográficos
Autores principales: Atzeni, Fabiola, Sarzi-Puttini, Piercarlo, Dell' Acqua, Donata, de Portu, Simona, Cecchini, Germana, Cruini, Carola, Carrabba, Mario, Meroni, Pier Luigi
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526573/
https://www.ncbi.nlm.nih.gov/pubmed/16356192
http://dx.doi.org/10.1186/ar1851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526573/
https://www.ncbi.nlm.nih.gov/pubmed/16356192
http://dx.doi.org/10.1186/ar1851

Ejemplares similares